Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Securities and Exchange Commission
Biotech
FibroGen pays SEC $1.2M over claims of 'reverse engineered' data
FibroGen has agreed to pay $1.25 million to the SEC to settle allegations that its former chief medical officer manipulated data for the anemia drug.
James Waldron
Sep 11, 2025 10:41am
Cassava pays $40M over allegedly misleading Alzheimer's update
Sep 27, 2024 9:20am
Allarity warned of pending SEC charges over FDA meeting conduct
Jul 22, 2024 9:50am
SEC joins DOJ in charging Stimwave ex-CEO with fraud
Dec 21, 2023 12:17pm
Man accused of insider trading tied to Pfizer's Array purchase
Oct 19, 2023 10:22am
SEC to probe Illumina acquisition amid Grail deal fallout
Aug 11, 2023 10:41am
